The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients
暂无分享,去创建一个
[1] W. Chung,et al. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer , 2018, Genetics in Medicine.
[2] T. Walsh,et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women , 2017, JAMA oncology.
[3] S. Ladelund,et al. Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types , 2017, British Journal of Cancer.
[4] Alain Viari,et al. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. , 2017, Cancer research.
[5] A. Chakravarti,et al. Abstract 4755: Calpastatin phosphorylation regulates radiation response in glioblastoma , 2017 .
[6] C. Gau,et al. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. S. Guraya,et al. Breast cancer screening programs: Review of merits, demerits, and recent recommendations practiced across the world , 2016, Journal of microscopy and ultrastructure.
[8] P. Ang,et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore , 2016, npj Genomic Medicine.
[9] Christopher D. Heinen,et al. Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.
[10] Aung Ko Win,et al. Risk of breast cancer in Lynch syndrome: a systematic review , 2013, Breast Cancer Research.
[11] Markus Loeffler,et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Friedman,et al. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer , 2012, Familial Cancer.
[13] S. Gruber,et al. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. , 2011, Gastroenterology.
[14] S. Gruber,et al. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome , 2011, Clinical genetics.
[15] E. Friedman,et al. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. , 2010, Gynecologic oncology.
[16] D. Bercovich,et al. An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC , 2010, Familial Cancer.
[17] P. Gregersen,et al. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. , 2002, American journal of human genetics.
[18] P. Dottino,et al. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. , 2000, Gynecologic oncology.
[19] W. Foulkes,et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.
[20] I. Bleiweiss,et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. , 1998, American journal of human genetics.
[21] Alfred A. Boyd,et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.
[22] E. Friedman,et al. The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. , 2016, Cancer genetics.
[23] E. Friedman,et al. The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. , 2016, Cancer genetics.
[24] Karla Bowles,et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.
[25] L. Norton,et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. , 1997, Genetic testing.